Wastewater sequencing uncovers early, cryptic SARS-CoV-2 variant transmission
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Summary
As SARS-CoV-2 continues to spread and evolve, detecting emerging variants early is critical for public health interventions. Inferring lineage prevalence by clinical testing is infeasible at scale, especially in areas with limited resources, participation, or testing/sequencing capacity, which can also introduce biases. SARS-CoV-2 RNA concentration in wastewater successfully tracks regional infection dynamics and provides less biased abundance estimates than clinical testing. Tracking virus genomic sequences in wastewater would improve community prevalence estimates and detect emerging variants. However, two factors limit wastewater-based genomic surveillance: low-quality sequence data and inability to estimate relative lineage abundance in mixed samples. Here, we resolve these critical issues to perform a high-resolution, 295-day wastewater and clinical sequencing effort, in the controlled environment of a large university campus and the broader context of the surrounding county. We develop and deploy improved virus concentration protocols and deconvolution software that fully resolve multiple virus strains from wastewater. We detect emerging variants of concern up to 14 days earlier in wastewater samples, and identify multiple instances of virus spread not captured by clinical genomic surveillance. Our study provides a scalable solution for wastewater genomic surveillance that allows early detection of SARS-CoV-2 variants and identification of cryptic transmission.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.protocols.io/view/high-throughput-wastewater-sars-cov-2-detection-pi-bshvnb66
Funding Statement
This work has been funded by CDC BAA contracts 75D30121P10258 (Helix) and 75D30120C09795 (G.W.Y., R.K., L.C.L., and K.G.A.), NIH NIAID 3U19AI135995-03S2 (K.G.A.), U19AI135995 (K.G.A.), U01AI151812 (K.G.A.), NIH NCATS UL1TR002550 (K.G.A.), the Conrad Prebys Foundation (K.G.A.), NIH 5T32AI007244-38 (J.I.L.), NIH Pioneer Grant 1DP1AT010885 (R.K), NSF RAPID 2029069 (R.K.), San Diego County Health and Human Services Agency (R.F.M), NIH S10OD026929 (K.J.). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of California San Diego Institutional Review Boards (IRB) provided human subject protection oversight of the of the data obtained by the EXCITE lab for the campus clinical samples (IRB approval #210699, #200477). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and any sample identifiers included were de-identified. The wastewater component of this project was discussed with our Institutional Review Board, and was not deemed to be human subject research, as it did not record personally identifiable information.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Senior author
Data Availability
Data availability and relevant links provided in the manuscript
https://searchcovid.info/dashboards/wastewater-surveillance/
Subject Area
- Addiction Medicine (342)
- Allergy and Immunology (665)
- Anesthesia (180)
- Cardiovascular Medicine (2625)
- Dermatology (222)
- Emergency Medicine (397)
- Epidemiology (12175)
- Forensic Medicine (10)
- Gastroenterology (756)
- Genetic and Genomic Medicine (4064)
- Geriatric Medicine (385)
- Health Economics (676)
- Health Informatics (2625)
- Health Policy (997)
- Hematology (360)
- HIV/AIDS (845)
- Medical Education (398)
- Medical Ethics (109)
- Nephrology (430)
- Neurology (3832)
- Nursing (209)
- Nutrition (570)
- Oncology (2008)
- Ophthalmology (581)
- Orthopedics (238)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (73)
- Pathology (471)
- Pediatrics (1107)
- Primary Care Research (447)
- Public and Global Health (6499)
- Radiology and Imaging (1390)
- Respiratory Medicine (869)
- Rheumatology (400)
- Sports Medicine (338)
- Surgery (441)
- Toxicology (52)
- Transplantation (185)
- Urology (165)